Ascentage Pharma Group International (AAPG)
NASDAQ: AAPG · Real-Time Price · USD
16.23
-0.87 (-5.09%)
Sep 1, 2026, 4:00 PM EDT - Market closed
AAPG Revenue
Ascentage Pharma Group International had revenue of 302.21M CNY in the half year ending June 30, 2026, a decrease of -63.31%. This brings the company's revenue in the last twelve months to 642.64M, up 64.52% year-over-year. In the year 2025, Ascentage Pharma Group International had annual revenue of 574.12M, down -41.46%.
Revenue (ttm)
642.64M CNY
Revenue Growth
+64.52%
P/S Ratio
15.92
Revenue / Employee
776,129 CNY
Employees
828
Market Cap
1.51B USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 574.12M | -406.53M | -41.46% |
| Dec 31, 2024 | 980.65M | 758.67M | 341.77% |
| Dec 31, 2023 | 221.98M | 12.27M | 5.85% |
| Dec 31, 2022 | 209.71M | 181.80M | 651.38% |
| Dec 31, 2021 | 27.91M | 15.46M | 124.18% |
| Dec 31, 2020 | 12.45M | -2.06M | -14.21% |
| Dec 31, 2019 | 14.51M | 7.71M | 113.21% |
| Dec 31, 2018 | 6.81M | 479.00K | 7.57% |
| Dec 31, 2017 | 6.33M | -1.34M | -17.46% |
| Dec 31, 2016 | 7.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Novavax | 413.80M |
| Syndax Pharmaceuticals | 252.25M |
| AnaptysBio | 232.39M |
| Apnimed | 120.15M |
| Maze Therapeutics | 20.00M |
| SL Science Holding | 3.27M |
AAPG News
- 1 hour ago - Ascentage Pharma to Participate in Four Upcoming Investor Conferences - GlobeNewsWire
- 12 days ago - Half Year 2026 Ascentage Pharma Group International Earnings Presentation Transcript - GuruFocus
- 12 days ago - Ascentage Pharma Group International H1 Earnings Call Highlights - MarketBeat
- 13 days ago - Ascentage Pharma Group International Earnings Call Transcript: H1 2026 - Transcripts
- 13 days ago - Ascentage Pharma Group International Earnings release: H1 2026 - Filings
- 13 days ago - Ascentage Pharma Group International Slides: H1 2026 - Filings
- 13 days ago - Ascentage Pharma Loss H1 Revenue Jumps 29%; Advances Olverembatinib And Lisaftoclax Programs - Nasdaq
- 13 days ago - Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates - GlobeNewsWire